Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
ESR1m
.
Show all posts
Showing posts with label
ESR1m
.
Show all posts
Tuesday, September 8, 2026
FDA Approves Veppanu (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
›
Arvinas, Inc. (Nasdaq: ARVN), with its partner Pfizer Inc. (NYSE: PFE), announced the U.S. Food and Drug Administration (FDA) approval f...
Saturday, April 11, 2026
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
›
Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food and Drug Administration (FDA) has...
›
Home
View web version
